277 related articles for article (PubMed ID: 33631216)
21. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis.
Lee A; Scott LJ
BioDrugs; 2020 Apr; 34(2):235-244. PubMed ID: 32207094
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
Zhang Z; Schmitt J; Wozel G; Kirch W
Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
25. Network meta-analyses of systemic treatments for psoriasis: a critical appraisal: Original Articles: Jabbar-Lopez ZK, Yiu ZZN, Ward V et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol 2017; 137:1646-54. Sbidian E, Chaimani A, Garcia-Doval I et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12:CD011535.
Ellis AG; Flohr C; Drucker AM
Br J Dermatol; 2019 Feb; 180(2):282-288. PubMed ID: 30347448
[TBL] [Abstract][Full Text] [Related]
26. Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials.
Loftus EV; Colombel JF; Schreiber S; Randall CW; Regueiro M; Ali T; Arendt C; Coarse J; Spearman M; Kosutic G
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1753-1762. PubMed ID: 27464588
[TBL] [Abstract][Full Text] [Related]
27. Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis.
Gao W; Yu B; Yan Y; Zhao L; Zhao R
Front Immunol; 2023; 14():1151977. PubMed ID: 37304299
[TBL] [Abstract][Full Text] [Related]
28. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
Corbett M; Chehadah F; Biswas M; Moe-Byrne T; Palmer S; Soares M; Walton M; Harden M; Ho P; Woolacott N; Bojke L
Health Technol Assess; 2017 Oct; 21(56):1-326. PubMed ID: 28976302
[TBL] [Abstract][Full Text] [Related]
29. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis.
Li W; Ghamrawi R; Haidari W; Feldman SR
Ann Pharmacother; 2020 Apr; 54(4):380-387. PubMed ID: 31672037
[No Abstract] [Full Text] [Related]
30. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
Crowley JJ; Warren RB; Cather JC
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1676-1684. PubMed ID: 31054215
[TBL] [Abstract][Full Text] [Related]
31. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Gordon KB; Lebwohl M; Papp KA; Bachelez H; Wu JJ; Langley RG; Blauvelt A; Kaplan B; Shah M; Zhao Y; Sinvhal R; Reich K
Br J Dermatol; 2022 Mar; 186(3):466-475. PubMed ID: 34652810
[TBL] [Abstract][Full Text] [Related]
32. Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?
Wright E; Yasmeen N; Malottki K; Sawyer LM; Borg E; Schwenke C; Warren RB
Dermatol Ther (Heidelb); 2021 Feb; 11(1):181-220. PubMed ID: 33351178
[TBL] [Abstract][Full Text] [Related]
33. Tildrakizumab: A Review of Phase II and III Clinical Trials.
Kolli SS; Gabros SD; Pona A; Cline A; Feldman SR
Ann Pharmacother; 2019 Apr; 53(4):413-418. PubMed ID: 30345790
[TBL] [Abstract][Full Text] [Related]
34. Meta-analysis and Indirect Comparisons: on Methods, Paradigms, and Biologic Treatments for Psoriasis.
Puig L
Actas Dermosifiliogr (Engl Ed); 2021 Mar; 112(3):203-215. PubMed ID: 33053367
[TBL] [Abstract][Full Text] [Related]
35. Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study.
Ruggiero A; Fabbrocicni G; Cacciapuoti S; Potestio L; Gallo L; Megna M
Clin Cosmet Investig Dermatol; 2023; 16():529-536. PubMed ID: 36873660
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysis.
Szebényi J; Gede N; Hegyi P; Szakács Z; Solymár M; Erőss B; Garami A; Farkas K; Csupor D; Gyulai R
Acta Derm Venereol; 2020 Nov; 100(18):adv00318. PubMed ID: 32965504
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
Blauvelt A; Leonardi CL; Gooderham M; Papp KA; Philipp S; Wu JJ; Igarashi A; Flack M; Geng Z; Wu T; Camez A; Williams D; Langley RG
JAMA Dermatol; 2020 Jun; 156(6):649-658. PubMed ID: 32267471
[TBL] [Abstract][Full Text] [Related]
38. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
39. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Lebwohl M; Leonardi C; Griffiths CE; Prinz JC; Szapary PO; Yeilding N; Guzzo C; Li S; Hsu MC; Strober B
J Am Acad Dermatol; 2012 May; 66(5):731-41. PubMed ID: 21930328
[TBL] [Abstract][Full Text] [Related]
40. Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis.
Fahrbach K; Sarri G; Phillippo DM; Neupane B; Martel SE; Kiri S; Reich K
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1965-1998. PubMed ID: 34549383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
